Skip to main content

Day: March 27, 2026

Borregaard ASA: Proxies for the Annual General Meeting 16 April 2026

In connection with Borregaard’s Annual General Meeting, Mr. Helge Aasen, Chair of the Board of Directors in Borregaard ASA, has been assigned voting rights based on proxies for 7,906,608 shares in Borregaard ASA. The proxies apply exclusively to the Annual General Meeting in Borregaard ASA on 16 April 2026. This means that Mr. Helge Aasen represents a total of 7,9% of the outstanding shares in Borregaard ASA. Mr. Helge Aasen’s shareholding in Borregaard ASA is 4,500 shares. Borregaard ASASarpsborg, 27 March 2026 Contact: Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act.

Continue reading

Vantiva – Estimated Operational Results Full Year 2025

Press Release Estimated Operational Results Full Year 2025 Vantiva meets its guidance at the budget forex rate ADJUSTED EBITDA: €145 MILLION vs €109 million in 20241(€155 MILLION at budget forex rate)FCF2 POSITIVE: €62 MILLION vs -€25 million in 2024(€71 MILLION at budget forex rate) Paris (France) – March 27, 2026 – Vantiva (Euronext Paris: VANTI), a global technology leader in connectivity, announces its estimated unaudited operational results for the year 2025. The accounting basis used for these estimates is consistent with the accounting methods applied by Vantiva and described in its consolidated financial statements. However, since some annual closing procedures for 2025 are not yet completed, the auditors’ opinion is still pending. The estimated financial data has been reviewed by Vantiva’s Board of Directors and is currently...

Continue reading

Helios Consortium Offer for CAB

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION         Update Statement TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — Introduction On 12 February 2026, the Helios Consortium announced a cash offer to acquire the entire issued and to be issued share capital of CAB Payments Holdings plc (“CAB Payments”), excluding CAB Payments shares already owned or controlled by Helios Fund III (the “Helios Offer Announcement”) (the “Helios Offer”). Under the terms of the Helios Offer, Eligible CAB Payments Shareholders would be entitled to receive US$1.15 in cash per existing CAB Payments share or the Partial Alternative Offer. The Helios Offer is supported by shareholders...

Continue reading

Novaturas Announces Changes in Chief Financial Officer Position

Novaturas Group announces a change in its executive team. As of March 27, Chief Financial Officer Auksė Kriaučiūnaitė is stepping down from her position. The company is currently conducting a search for a new candidate. “We are grateful to Auksė for her significant contribution and for taking on the responsibility of leading the finance team during a particularly dynamic period. We are glad to have worked together over these years and wish her the best of success in her future career,” says Novaturas CEO Ieva Galvydienė. The company is currently searching for a new Chief Financial Officer who will oversee operations across Lithuania, Latvia, and Estonia. During the selection process, CFO responsibilities will be ensured through internal resources. About the company The Novaturas Group is a tour operator offering the widest range of travel...

Continue reading

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases   – Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression   – Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience  Basel, March 27, 2026 – Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase 1.   The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in...

Continue reading

IBA delivers strong FY 2025 results with solid execution in all segments   

Read the entire full-year 2025 results press release hereLouvain-la-Neuve, Belgium, 27 March 2026 – IBA (Ion Beam Applications S.A.), today announces its consolidated results of 2025 financial year, with strong execution across the businesses. Robust commercial momentum, notably in Proton Therapy, resulted in a historic order intake and a new all-time high backlog. Delivered in line with guidance, the year marks continued progress in the execution of IBA’s strategic roadmap to the benefit of all its stakeholders.Record-high revenue and enhanced profitabilityNet sales rose 24% vs. 2024, to €620 million, thanks to well-executed backlog conversion in IBA Clinical (+44% net sales growth) Gross margin decreased to 32.2% vs. 33.7% in 2024, driven by less favorable equipment profitability mix (including legacy low-margin projects...

Continue reading

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

– Acquisition brings together Excellergy’s differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion – – Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development – PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE) — Excellergy, a biotechnology company developing a novel class of allergy therapeutics, today announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy’s novel trifunctional ECRIs with the development expertise of Novartis. Exl-111 is a trifunctional ECRI designed to disarm allergic effector...

Continue reading

Icelandic Salmon – Annual Report 2025

Icelandic Salmon AS (Euronext Growth Oslo and First North Iceland: ISLAX) hastoday published its integrated Annual Report for 2025, including sustainabilityreporting and complete annual accounts with notes. The report is attached and available on the following website: https://arnarlax.is/investors/ For further information, please contact:CEO Bjørn HembreTel: +354 620 1936Email: bjorn@arnarlax.is Interim CFO Edvin AspliTel: +354 835 7800Email: edvinaspli@arnarlax.is Icelandic Salmon is dual-listed on the stock exchange market, both at the Euronext Growth in Oslo and NASDAQ First North in Reykjavík. The Group is the 100% owner of Arnarlax ehf, a farming company in Iceland with head office in Bíldudalur. The Group is fully integrated, from egg to fish delivered to customers in the market, with control over all parts of the value chain. See...

Continue reading

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share (such offering, the “Equity Offering”). Zenas estimates that the aggregate net proceeds from the Convertible Notes Offering and the Equity Offering will be...

Continue reading

Colabor Group Inc. Provides Update on Its SISP

SAINT-BRUNO-DE-MONTARVILLE, Québec, March 26, 2026 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) provided today an update regarding its sale and investment solicitation process (“SISP”) conducted under the supervision of the Superior Court of Québec (Commercial Division) (the “Court”) and Raymond Chabot Inc., as Court-appointed monitor of the Company (the “Monitor”) in connection with the restructuring proceedings (the “CCAA Proceedings”) of the Company and certain of its subsidiaries, Transport Paul-Émile Dubé Ltée, Le Groupe Resto-Achats Inc. and Norref Fisheries Quebec Inc., instituted on January 8, 2026, under the Companies’ Creditors Arrangement Act (Canada). The Company continues to make progress with its SISP with the assistance of the Monitor, and has accepted four binding offers for the substantial...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.